Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.41 |
| ▸ | F3 | P13726 | 3/20 | 0.40 |
| ▸ | F7 | P08709 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765749 | 0.96 | F2 (0.38) | F2PRSS1F3F7PRSS2 | |
| SCHEMBL30765820 | 0.86 | CMA1 (0.40) | F2PRSS1F3F7NTRK1 | |
| SCHEMBL30765583 | 0.86 | F2 (0.40) | F2PRSS1F3F7PRSS2 | |
| SCHEMBL30766049 | 0.86 | NTRK1 (0.43) | F2F3F7NTRK1CMA1 | |
| SCHEMBL30765550 | 0.85 | F2 (0.38) | F2PRSS1F3F7NTRK1 | |
| Hydrochloric Acid SCHEMBL30765434 | 0.85 | NTRK1 (0.43) | F2F3F7NTRK1CMA1 | |
| SCHEMBL30765697 | 0.85 | F2 (0.43) | F2PRSS1F3PRSS2PRSS3 | |
| SCHEMBL30765437 | 0.84 | HDAC6 (0.41) | F2PRSS1F3F7CMA1 | |
| SCHEMBL30765489 | 0.84 | F2 (0.39) | F2PRSS1F3F7PRSS2 | |
| SCHEMBL23511258 | 0.84 | F2 (0.51) | F2PRSS1PRSS2PRSS3MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |